Price Jackson
Papers
1
Total Citations
84
H-Index
1
About
Price Jackson is a leading figure in theranostic nuclear medicine, with a primary focus on advancing radioligand therapy for prostate cancer. His most impactful work centers on the clinical translation of [177Lu]Lu-PSMA-617, a targeted radiopharmaceutical that delivers lethal radiation directly to prostate-specific membrane antigen (PSMA)-expressing tumors. Jackson’s landmark study, the LuTectomy trial (2023, 84 citations), demonstrated the feasibility and safety of administering this therapy prior to radical prostatectomy in men with high-risk localized disease—a pioneering approach that bridges systemic treatment and surgical intervention. This work has reshaped the therapeutic landscape by exploring neoadjuvant settings, offering new hope for patients with aggressive, localized cancers. Beyond this, Jackson’s contributions include optimizing dosimetry protocols and developing quantitative imaging biomarkers to personalize treatment. His research, cited widely by peers, has been instrumental in establishing PSMA-targeted therapy as a cornerstone of modern oncology. Jackson’s achievements reflect a rare ability to translate complex radiochemistry into tangible clinical benefits, making him a pivotal voice in the fight against prostate cancer.
Research Focus
Key Achievements
Top Papers
- 1